Philippines - English - FDA (Food And Drug Administration)

ambica international trading corporation; distributor: united pharma plus (unipharma), inc. - pantoprazole (as sodium) - powder for iv injection - 40 mg

Philippines - English - FDA (Food And Drug Administration)

euro generics international phils., inc.; distributor: united pharma plus (unipharma), inc. - trimetazidine hydrochloride - modified release tablet - 35mg

Philippines - English - FDA (Food And Drug Administration)

ambica international corporation; distributor: united pharma plus (unipharma) inc. - diosmin , hesperidin - film-coated tablet - 450mg/50 mg

Philippines - English - FDA (Food And Drug Administration)

pharmakon biotec inc.; distributor: united pharma plus (unipharma) inc. - cefuroxime (sodium) - powder for injection (im/iv) - 750 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: gpc geo pharma corporation; distributor: united pharma plus (unipharma) inc. - cefuroxime (as sodium) - powder for injection (im/iv) - 750 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

European Union - English - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel hydrochloride - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease., - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy., , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke., , for further information please refer to section 5.1. , , ,

European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - docetaxel - carcinoma, non-small-cell lung; breast neoplasms; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel teva pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.non-small-cell lung cancerdocetaxel teva pharma is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.docetaxel teva pharma in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel teva pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

United States - English - NLM (National Library of Medicine)

mylan consumer healthcare, inc. - zinc gluconate (unii: u6wsn5sq1z) (zinc cation - unii:13s1s8sf37), sambucus nigra flower (unii: 07v4dx094t) (sambucus nigra flower - unii:07v4dx094t), glycyrrhiza glabra leaf (unii: gh32m797y9) (glycyrrhiza glabra leaf - unii:gh32m797y9) - cold remedy relieves cough, nasal congestion and irritated respiratory tract* relieves irritated throat* taking minocycline, doxycycline, tetracycline or are on coumadin (warfarin) therapy. zinc treatment may inhibit the absorption of these medicines. symptoms persist beyond 7 days

United States - English - NLM (National Library of Medicine)

mylan consumer healthcare, inc. - zinc gluconate (unii: u6wsn5sq1z) (zinc cation - unii:13s1s8sf37), sambucus nigra flower (unii: 07v4dx094t) (sambucus nigra flower - unii:07v4dx094t), glycyrrhiza glabra leaf (unii: gh32m797y9) (glycyrrhiza glabra leaf - unii:gh32m797y9) - cold remedy relieves cough, nasal congestion and irritated respiratory tract* relieves irritated throat* taking minocycline, doxycycline, tetracycline or are on coumadin (warfarin) therapy. zinc treatment may inhibit the absorption of these medicines. symptoms persist beyond 7 days